Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
2.
Indian J Exp Biol ; 2014 Nov; 52(11): 1090-1097
Article in English | IMSEAR | ID: sea-153795

ABSTRACT

The present study describes a novel and simple vaccination strategy that involve culturing of M. tuberculosis in the macrophage cells. Isolation of phagosome from macrophage (cell line J774) infected with M. tuberculosis (H37) and M. bovis (BCG) at early and late phase of infection was done ensuing the identification and characterization of these phagosome. In vitro study of apoptosis induced by phagosome infected with (H37) and (BCG) was performed. The vaccine candidate with H37 MOI- 1:10 at 3 h, MOI- 1:20 at 1, 1.5, 2.5 and 3 h and BCG MOI- 1:20 at 3.5 h showed percentage apoptosis as 38.64, 39.93, 34.66, 22.56,34.59 and 37.81% respectively. The results designates that macrophages provide cellular niche during infection and illustrate considerable immunogenic property. Novel antigens expressed or secreted by H37 in infected macrophages can provide evidence to be a successful vaccine candidate as it endures enhanced immune response than BCG.


Subject(s)
Animals , Antigens, Bacterial/immunology , Apoptosis , Cell Line, Tumor , Culture Media , DNA Fragmentation , Lymphoma, Non-Hodgkin/pathology , Macrophages/microbiology , Mice , Mice, Inbred BALB C , Mycobacterium bovis/growth & development , Mycobacterium bovis/immunology , Mycobacterium tuberculosis/growth & development , Mycobacterium tuberculosis/immunology , Phagosomes/immunology , Phagosomes/microbiology , Tuberculosis Vaccines/immunology , Tuberculosis Vaccines/isolation & purification
3.
Braz. j. med. biol. res ; 45(12): 1183-1194, Dec. 2012. ilus, mapas, tab
Article in English | LILACS | ID: lil-659642

ABSTRACT

In the last several years, the use of dendritic cells has been studied as a therapeutic strategy against tumors. Dendritic cells can be pulsed with peptides or full-length protein, or they can be transfected with DNA or RNA. However, comparative studies suggest that transfecting dendritic cells with messenger RNA (mRNA) is superior to other antigen-loading techniques in generating immunocompetent dendritic cells. In the present study, we evaluated a new therapeutic strategy to fight tuberculosis using dendritic cells and macrophages transfected with Hsp65 mRNA. First, we demonstrated that antigen-presenting cells transfected with Hsp65 mRNA exhibit a higher level of expression of co-stimulatory molecules, suggesting that Hsp65 mRNA has immunostimulatory properties. We also demonstrated that spleen cells obtained from animals immunized with mock and Hsp65 mRNA-transfected dendritic cells were able to generate a mixed Th1/Th2 response with production not only of IFN-γ but also of IL-5 and IL-10. In contrast, cells recovered from mice immunized with Hsp65 mRNA-transfected macrophages were able to produce only IL-5. When mice were infected with Mycobacterium tuberculosis and treated with antigen-presenting cells transfected with Hsp65 mRNA (therapeutic immunization), we did not detect any decrease in the lung bacterial load or any preservation of the lung parenchyma, indicating the inability of transfected cells to confer curative effects against tuberculosis. In spite of the lack of therapeutic efficacy, this study reports for the first time the use of antigen-presenting cells transfected with mRNA in experimental tuberculosis.


Subject(s)
Animals , Male , Mice , Antigen-Presenting Cells/immunology , Bacterial Proteins/administration & dosage , /administration & dosage , Mycobacterium tuberculosis/immunology , RNA, Messenger/immunology , Tuberculosis Vaccines/administration & dosage , Tuberculosis/immunology , Bacterial Proteins/adverse effects , Bacterial Proteins/immunology , /adverse effects , /immunology , Mice, Inbred BALB C , RNA, Messenger/adverse effects , Spleen/immunology , Transfection , Tuberculosis Vaccines/adverse effects , Tuberculosis Vaccines/immunology , Tuberculosis/prevention & control
4.
Rev. cuba. med. trop ; 64(3): 279-289, jul.-sep. 2012.
Article in Spanish | LILACS | ID: lil-653846

ABSTRACT

Introducción: el desarrollo de nuevas vacunas antituberculosas requiere de la caracterización de la respuesta de inmunidad celular, inducida por el nuevo candidato vacunal frente a los antígenos principales de Mycobacterium tuberculosis. Objetivo: determinar el potencial inmunogénico de ´Mycobacterium habana´ TMC-5135, cuando se usa como vacuna subcutánea en ratones Balb/c. Métodos: en este estudio se inocularon subcutáneamente ratones Balb/c con la cepa viva ´Mycobacterium habana´ TMC-5135 y se determinó la producción in vitro de IFN gamma en cultivos celulares de pulmón, bazo y ganglios inguinales estimulados con antígenos solubles totales y el antígeno 85b. Como grupo control se vacunaron ratones con BCG subcepa Phipps. Resultados: particularmente en los ganglios linfáticos inguinales, ambos antígenos indujeron mayor producción de IFN gamma en los ratones vacunados con ´Mycobacterium habana´que con BCG. Conclusiones: los resultados justifican la realización de nuevas investigaciones usando ´Mycobacterium habana´ TMC-5135 como candidato vacunal para prevenir la tuberculosis.


Introduction: development of new antituberculosis vaccines requires the characterization of the cell-mediated immune responses induced by mycobacterial antigens. Objective: to determine the immunogenic potential of ´Mycobacterium habana´ TMC-5135 when using subcutaneous vaccine in Balb/c mice. Methods: in this study, Balb/c mice were inoculated subcutaneously with live ´Mycobacterium habana´ TMC-5135. The production of IFN gamma in cell suspensions obtained from the lungs, the spleen and the lymph nodes after stimulation with mycobacterial antigens Ag85b or culture filtrate antigens (CFA) was recorded. Results: the production of IFN gamma after stimulation with CFA and Ag85b was higher in mice vaccinated with ´M. habana´ than in animals immunized with BCG. Conclusions: these results encourage new research on ´M. habana´ as vaccinal candidate against tuberculosis.


Subject(s)
Animals , Male , Mice , Antigens, Bacterial/immunology , Interferon-gamma/biosynthesis , Nontuberculous Mycobacteria/immunology , Tuberculosis Vaccines/immunology , Mice, Inbred BALB C
5.
Braz. j. infect. dis ; 16(1): 68-73, Jan.-Feb. 2012. ilus
Article in English | LILACS | ID: lil-614553

ABSTRACT

The development of diagnostic tests which can readily differentiate between vaccinated and tuberculosis-infected individuals is crucial for the wider utilization of bacillus Calmette-Guérin (BCG) as vaccine in humans and animals. BCG_0092 is an antigen that elicits specific delayed type hypersensitivity reactions similar in size and morphological aspects to that elicited by purified protein derivative, in both animals and humans infected with the tubercle bacilli. We carried out bioinformatics analyses of the BCG_0092 and designed a diagnostic test by using the predicted MHC class I epitopes. In addition, we performed a knockout of this gene by homologous recombination in the BCG vaccine strain to allow differentiation of vaccinated from infected individuals. For that, the flanking sequences of the target gene (BCG_0092)were cloned into a suicide vector. Spontaneous double crossovers, which result in wild type revertants or knockouts were selected using SacB. BCG_0092 is present only in members of the Mycobacterium tuberculosis complex. Eight predicted MHC class I epitopes with potential for immunological diagnosis were defined, allowing the design of a specific diagnostic test. The strategy used to delete the (BCG_0092) gene from BCG was successful. The knockout genotype was confirmed by PCR and by Southern blot. The mutant BCG strain has the potential of inducing protection against tuberculosis without interfering with the diagnostic test based on the use of selected epitopes from BCG_0092.


Subject(s)
Humans , Adjuvants, Immunologic , Epitopes, T-Lymphocyte/immunology , Mycobacterium tuberculosis/immunology , Tuberculosis/diagnosis , Tuberculosis/immunology , BCG Vaccine/immunology , Computational Biology , Epitopes, T-Lymphocyte/analysis , Gene Knockout Techniques , Histocompatibility Antigens Class I/immunology , Hypersensitivity, Delayed/immunology , Mycobacterium bovis/genetics , Mycobacterium bovis/immunology , Mycobacterium tuberculosis/genetics , Tuberculosis Vaccines/immunology , Tuberculosis/prevention & control
6.
Braz. j. med. biol. res ; 40(11): 1495-1504, Nov. 2007. graf
Article in English | LILACS | ID: lil-464311

ABSTRACT

We previously reported that a DNA vaccine constructed with the heat shock protein (HSP65) gene from Mycobacterium leprae (DNA-HSP65) was protective and also therapeutic in experimental tuberculosis. By the intramuscular route, this vaccine elicited a predominant Th1 response that was consistent with its protective efficacy against tuberculosis. It has been suggested that the immune response to Hsp60/65 may be the link between exposure to microorganisms and increased cardiovascular risk. Additionally, the high cholesterol levels found in atherosclerosis could modulate host immunity. In this context, we evaluated if an atherogenic diet could modulate the immune response induced by the DNA-HSP65 vaccine. C57BL/6 mice (4-6 animals per group) were initially submitted to a protocol of atherosclerosis induction and then immunized by the intramuscular or intradermal route with 4 doses of 100 mug DNA-HSP65. On day 150 (15 days after the last immunization), the animals were sacrificed and antibodies and cytokines were determined. Vaccination by the intramuscular route induced high levels of anti-Hsp65 IgG2a antibodies, but not anti-Hsp65 IgG1 antibodies and a significant production of IL-6, IFN-g and IL-10, but not IL-5, indicating a Th1 profile. Immunization by the intradermal route triggered a mixed pattern (Th1/Th2) characterized by synthesis of anti-Hsp65 IgG2a and IgG1 antibodies and production of high levels of IL-5, IL-6, IL-10, and IFN-g. These results indicate that experimentally induced atherosclerosis did not affect the ability of DNA-HSP65 to induce a predominant Th1 response that is potentially protective against tuberculosis.


Subject(s)
Animals , Female , Mice , Atherosclerosis/immunology , Bacterial Proteins/immunology , Chaperonins/immunology , Th1 Cells/immunology , Tuberculosis Vaccines/immunology , Vaccines, DNA/immunology , Autoantibodies/blood , Autoantibodies/immunology , Bacterial Proteins/administration & dosage , Chaperonins/administration & dosage , Cytokines/blood , Cytokines/immunology , Diet, Atherogenic , Injections, Intradermal , Injections, Intramuscular , Immunoglobulin G/blood , Immunoglobulin G/immunology , Specific Pathogen-Free Organisms , Tuberculosis Vaccines/administration & dosage , Tuberculosis/immunology , Tuberculosis/prevention & control , Vaccines, DNA/administration & dosage
7.
Indian J Exp Biol ; 2005 Dec; 43(12): 1196-8
Article in English | IMSEAR | ID: sea-56963

ABSTRACT

Monospecific antibodies have been successfully utilized in antigen detection, which is better indicator of active infection. Mycobacterium tuberculosis excretory secretory (M tb ES) antigens such as ES 31, ES 41 and ES 43 (31 kDa, 41 kDa and 43 kDa protein, respectively) have been shown to be present in Mycobacterium tuberculosis H37Ra culture filtrate and are of diagnostic interest. To study the immunogenic potential of crude versus purified antigen, goat was immunized with M tb detergent soluble sonicate (DSS) antigen as well as purified antigen fraction (ESAS 7) containing ES 31 antigen. Both anti-DSS IgG antibody and anti ESAS 7 IgG antibody were found to be reactive with ES 31 antigen upto 1 ng concentration of antibody by ELISA. Crude DSS antigen was found to be quite effective in producing high titre antibodies and showed further high reactivity with other ES antigens (ES 41 and ES 43) of diagnostic interest.


Subject(s)
Animals , Antibodies, Bacterial/biosynthesis , Antigens, Bacterial/immunology , Bacterial Proteins/immunology , Goats/immunology , Mycobacterium/immunology , Mycobacterium tuberculosis/immunology , Tuberculosis Vaccines/immunology
8.
Indian J Pediatr ; 2002 Nov; 69 Suppl 1(): S29-38
Article in English | IMSEAR | ID: sea-81415

ABSTRACT

The availability of the complete genome sequence of Mycobacterium tuberculosis has provided us with unprecedented opportunities for understanding the biology of this highly successful pathogen and its unique interaction with the host. It is hoped that the impetus so provided to mycobacterial research will accelerate the development of effective and novel strategies for the treatment, prevention and detection of tuberculosis.


Subject(s)
Antitubercular Agents/therapeutic use , Drug Resistance, Multiple, Bacterial/genetics , Gene Expression Regulation, Bacterial/genetics , Genome, Bacterial , Humans , Mycobacterium tuberculosis/genetics , Signal Transduction/genetics , Tuberculosis Vaccines/immunology , Tuberculosis, Pulmonary/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL